19 results
424B5
ANVS
Annovis Bio Inc
1 Nov 23
Prospectus supplement for primary offering
12:24pm
direct competitors, including about adverse developments related to safety, effectiveness, accuracy and usability of their products, reputational concerns … confidence and raise reputational issues and may subject us to additional risks and uncertainties, including increased professional costs and the increased
424B5
ANVS
Annovis Bio Inc
30 Oct 23
Prospectus supplement for primary offering
5:27pm
developments related to safety, effectiveness, accuracy and usability of their products, reputational concerns, reimbursement coverage, regulatory … common stock.
The restatement of our prior quarterly financial statements may affect investor confidence and raise reputational issues and may
10-K
thntdeu3a0h60ug3golh
25 Mar 20
Annual report
4:45pm
424B5
431810ck9f5v2v0uts6
18 Mar 24
Prospectus supplement for primary offering
8:51pm
424B5
4wi0z600 alyv
18 Mar 24
Prospectus supplement for primary offering
10:00pm
424B5
k2i ql79c3
1 May 24
Prospectus supplement for primary offering
4:50pm
DRS
gle k1kb2
15 May 19
Draft registration statement
12:00am
DRS/A
qox9k2cx8zj jlk
24 May 19
Draft registration statement (amended)
12:00am
424B4
tiofy ourwq935v
30 Jan 20
Prospectus supplement with pricing info
6:07am
S-1
ibzoe32i
2 Jul 19
IPO registration
9:15pm
S-1/A
1fw2t5vr9p5 fdg4
8 Aug 19
IPO registration (amended)
5:23pm
- Prev
- 1
- Next